The role of new targeted therapies in small-cell lung cancer

Critical Reviews in Oncology/Hematology

Volumn 51, Issue 1, 2004, Pages 45-53

  Rossi, A ^a   Maione, P ^a   Colantuoni, G ^a   Guerriero, C ^a   Gridelli, C ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

New targeted therapies; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CANCER VACCINE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IMATINIB; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MITUMOMAB; NAVELBINE; OBLIMERSEN; PROTEASOME INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TANOMASTAT; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; VANDETANIB; ZOLEDRONIC ACID;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERANCE; FATIGUE; GENE THERAPY; GRANULOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; LUNG SMALL CELL CANCER; NAUSEA; NEPHROTOXICITY; NONHUMAN; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, SMALL CELL; CLINICAL TRIALS, PHASE III; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGORIBONUCLEOTIDES, ANTISENSE;

EID: 2942652393     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.02.003     Document Type: Review

References (70)

1. Jemal A., Murray T., Samuels A, et al. Cancer statistics 2003. Can. Cancer J. Clin. 53:2003;5-26
2. Elias D. Small cell lung cancer: state-of-the-art therapy in 1996. Chest. 112:1997;251S-258S
3. Patel A.M., Dunn W.F., Trastek V.F. Staging systems of lung cancer. Mayo Clin. Proc. 68:1993;475-482
4. Ihde D.C. Chemotherapy of lung cancer. N. Engl. J. Med. 327:1992;1434-1441
5. Turrisi A.T. 3rd, Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N. Engl. J. Med. 340:1999;265-271
6. Gridelli C., Perrone F., Monfardini S. Lung cancer in the elderly. Eur. J. Cancer. 33:1997;2313-2314
7. Gridelli C., De Vivo R., Monfardini S. Management of small-cell lung cancer. Crit. Rev. Oncol. Hematol. 41:2002;79-88
8. Michael M., Babic B., Khokha R., et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol. 17:1999;1802-1808
9. Shepherd F.A., Giaccone G., Seymour L., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J. Clin. Oncol. 20:2002;4434-4439
10. Rigas J.R., Denham C.A., Rinaldi D., et al. Adjuvant targeted therapy in unresectable lung cancer: the results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI). Lung Cancer. 41(Suppl. 2):2003;S34. [abstr O107]
11. Kerbel R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21:2000;505-515
12. Liekens S., De Clercq E., Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61:2001;253-270
13. Lucchi M., Mussi A., Fontanini G., Faviana P., Ribechini A., Angeletti C.A. Small cell lung carcinoma (SCLC): the angiogenesis phenomenon. Eur. J. Cardiothorac. Surg. 21:2002;1105-1110
14. Dowell J., Amirkhan R.H., Lai W.S., Minna J. Survival in small cell lung cancer (SCLC) is independent of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) expression. Proc. Am. Soc. Clin. Oncol. 22:2003;632. [abstr 2541]
15. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:1994;4082-4085
16. James L.E., Lee A.M. A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC). Lung Cancer. 41(Suppl. 2):2003;S183. [abstr P363]
17. Phase I study of thalidomide in patients with extensive-stage small cell lung cancer who achieve a complete or partial response to induction chemotherapy. Protocol IDs: CWRU-1502, CELGENE-CWRU-1502. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 4 February 2004.
18. Phase III randomized study of carboplatin and etoposide with versus without thalidomide in patients with limited or extensive stage small cell lung cancer. Protocol IDs: LLCG-STUDY-12, EU-20207. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 4 February 2004.
19. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62:2002;284-290
20. Wedge S.R., Ogilvie D.J., Dukes M. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62:2002;4645-4655
21. Phase II randomized study of ZD6474 in patients with small cell lung cancer who responded to induction chemotherapy with or without radiotherapy. Protocol IDs: CAN-NCIC-BR20, ZENECA-6474IL/0005. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 4 February 2004.
22. Yarden Y., Kuang W.J., Yang-Fen T., et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine for an unidentified ligand. EMBO J. 6:1987;3341-3351
23. Krystal G.W., Hines S.J., Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 56:1996;370-376
24. Dy G.K., Adjei A.A. Novel targets for lung cancer therapy: part I. J. Clin. Oncol. 20:2002;2881-2894
25. Krystal G.W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor ST571 inhibits small cell lung cancer growth. Clin. Cancer Res. 6:2000;3319-3326
26. Talpaz M., Silver R.T., Druker B.J., et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99:2002;1928-1937
27. Heinrich M.C., Blanke C.D., Druker B.J., Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20:2002;1692-1703
28. van Oosterom A.T., Judson I.R., Verweij J., et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer. 38:2002;S83-S87
29. Johnson B.E., Fisher T., Fisher B., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. 9:2003;5880-5887
30. Micke P., Basrai M., Faldun A., et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res. 9:2003;188-194
31. Vlahovic G., Kelley M.J. Effect of STI571 on in vitro cytotoxicity of vinorelbine and topotecan in lung cancer cell lines. Lung Cancer. 41(Suppl. 2):2003;S181. [abstr P355]
32. Matsumoto S., Kimura A., Ito S., et al. Combination efficacy of bisphosphonate, zoledronate with imatinib mesylate (Gleevec) in small cell lung cancer cell line. Lung Cancer. 41(Suppl. 2):2003;S249. [abstr P623]
33. Tamberi S., Longo L., Rossi G., et al. Loss of kit expression after chemotherapy in small cell lung cancer: therapeutic implications. Proc. Am. Soc. Clin. Oncol. 22:2003;648. [abstr 2607]
34. Burger H., den Bakker M.A., Stoter G., Verweij J., Nooter K. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur. J. Cancer. 39:2003;793-799
35. Phase I study of imatinib mesylate, irinotecan, and cisplatin in patients with extensive stage small cell lung cancer. Protocol IDs: MSKCC-02015, NCI-5653. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 4 February 2004.
36. Phase I study of cisplatin, irinotecan, and imatinib mesylate in patients with extensive stage small cell lung cancer. Protocol IDs: PMH-PHL-008, NCI-5684. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 4 February 2004.
37. Phase II study of imatinib mesylate in patients with recurrent small cell lung cancer. Protocol IDs: NCCTG-N0124, CALGB-30201. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 4 February 2004.
38. Clarke S. Protein isoprenylation and methylation at carboxyl terminal cysteine residues. Annu. Rev. Biochem. 61:1992;355-386
39. James G.L., Goldstein G.L., Pathak R.K., Anderson R.G., Brown M.S. PxF, a prenylated protein of peroxisomes. J. Biol. Chem. 269:1994;14182-14190
40. Farnsworth C.C., Wolda S.L., Gelb M.H., Glomset J.A. Human lamin B contains a farnesylated cysteine residue. J. Biol. Chem. 264:1989;20422-20429
41. Heymach J.V., De Porre P.M., DeVore R.F., et al. Phase II study of the farnesyl transferase inhibitor (FTI) R115777 (Zarnestra) in patients with relapsed small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;319a. [abstr 1275]
42. Fuentes R., Allman R., Mason M.D. Ganglioside expression in lung cancer cell lines. Lung Cancer. 18:1997;21-33
43. Vangsted A.J., Clausen H., Kjeldsen T.B., et al. Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum. Cancer Res. 51:1991;2879-2884
44. Grant S.C., Kris M.G., Houghton A.N., Chapman P.B. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin. Cancer Res. 5:1999;1319-1323
45. Krug M.L., Ragupathi G., Livingstone P.O., et al. Pilot trial of a synthetic fucosyl-GM1 ganglioside vaccine in patients with small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;4b. [abstr 1824]
46. Ng K.K., Kris M.G., Miller V.A., et al. Vaccination with polysialic acid (polySA)-KLH or N-propyolinated (NP) polysialic acid-keyole limpet hemocyanin (KLH) conjugate plus QS-21 in patients with small cell lung cancer (SCLC) after a major response therapy. Proc. Am. Soc. Clin. Oncol. 20:2001;223b. [abstr 2644]
47. Krug L.M., Ragupathi G., Kris M.G., et al. Development of a tetravalent small cell lung cancer (SCLC) vaccine containing GM2, fucosyl GM1, Globo H, and polysialic acid. Lung Cancer. 41(Suppl. 2):2003;S47. [abstr O154]
48. Bhattacharya-Chatterjee M., Chatterjee S.K., Foon K.A., et al. Anti-idiotype antibody vaccine therapy for cancer. Expert. Opin. Biol. Ther. 2:2002;869-881
49. Reece D.E., Foon K.A., Bhattacharya-Chatterjee M., et al. Interim analysis of the use of anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin. Breast Cancer. 2:2001;52-58
50. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52:1992;4828-4831
51. Hamada M., Fujiwara T., Hizuta A., et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J. Cancer Res. Clin. Oncol. 122:1996;360-365
52. Phase I/II study of autologous dendritic cell-adenovirus p53 after standard chemotherapy in patients with extensive stage small cell lung cancer. Protocol IDs: MCC-13427, MCC-0205538, MCC-12614, MCC-6260, MCC-IRB-0147/NE. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 4 February 2004.
53. Jansen B., Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol. 3:2002;672-683
54. Rudin C.M., Otterson G.A., Mauer A.M., et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol. 13:2002;539-545
55. Rudin C., Kosloff M., Edelman M.J., Hoffman P.C., Szeto L., Vokes E.E. Phase I study of G3139 (oblimersen sodium), carboplatin, and etoposide in previously untreated extensive stage small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 22:2003;631. [abstr 2538]
56. Phase II randomized study of carboplatin and etoposide with or without oblimersen in patients with extensive stage small cell lung cancer. Protocol IDs: CALGB-30103. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 4 February 2004.
57. Stolovich M., Tang H., Hornstein E., et al. Transduction of growth of mitogenic signals into translational activation of TOR mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1nor rpS6 phosphorylation. Mol. Cell Biol. 22:2002;8101-8113
58. Grunwald V., DeGranffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reserve doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 62:2002;6141-6145
59. Hidalgo M., Rowinsky E., Erlichman C., et al. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. Proc. Am. Soc. Clin. Oncol. 19:2000;187a. [abstr 726]
60. Raymond E., Alexandre J., Depenbrock H., et al. CCI-779, a rapamycin analog with antitumor activity: a phase I study utilizing a weekly schedule. Proc. Am. Soc. Clin. Oncol. 19:2000;187a. [abstr 728]
61. Phase II randomized study of CCI-779 in patients with extensive-stage small cell lung cancer. Protocol IDs: E-E1500. Available at: http://www.nci.nih.gov/clinicaltrials. Accessed 26 September 2003.
62. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 8:2002;2505-2511
63. Phase II study of bortezomib in patients with recurrent or refractory extensive stage small cell lung cancer previously treated with platinum-based therapy. Protocol IDs: SWOG-S0327. Available at: http://www.nci.nih.gov/ clinicaltrials. Accessed 4 February 2004.
64. Bunn P.A., Shepherd F.A., Sandler A., et al. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer. 41:2003;S175-S186
65. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:1995;183-232
66. Micke P., Hengstler J.G., Bittinger F., et al. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int. J. Cancer. 92:2001;474-479
67. Potti A., Willardson J., Forseen C., et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer. 36:2002;257-261
68. Bunn P.A., Shepherd F.A., Sandler A., et al. Ongoing and future trials of biological therapies in lung cancer. Lung Cancer. 41:2003;S175-S186
69. Maulik G., Kijima T., Ma P.C., et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin. Cancer Res. 8:2002;620-627
70. Maulik G., Madhiwala P., Rajgor M., et al. c-Met/HGF signaling through P13K with effects on cytoskeletal functions in small cell lung cancer. Lung Cancer. 41(Suppl. 2):2003;S173. [abstr P324]